explore -WSS

explore

author：focus 2025-09-14 08:22:19 - browse：41

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Inaction leaves children at risk from dangerous chemotherapy drug

WSS

France's anti

High breast density mammograms need follow

Medicare drug price lawsuits could be good politics for Biden

Vermont grapples with historic flooding as more rainstorms head for Northeast

Mass General, Mayo Clinic look to monetize custom

Sickle cell gene therapy cures need to be accessible in Africa

focus

explore

knowledge

Peter Hotez and the public health issue of online harassment

Cardiologists urge adding sexual orientation, gender identity to health records

Alkermes shareholders re

Printout prescription drug information shouldn’t go digital

Hepatitis C has a cure — but many Americans still lack access to it

There's an unseen cost to disruptive road

Wildfire smoke exposes gaps in outdoor worker protections

CVS is on a mission to consolidate health care. Will it work?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Dog Aging Project founders on what lies ahead after losing funding

hotspot

Prior authorization reform is both possible and imperative

Maisha Meds is a PBM, but don't call it that

Medicare drug price lawsuits could be good politics for Biden

One Duchenne patient's bittersweet hope for new treatment

Medicare drug price lawsuits could be good politics for Biden

Sickle cell gene therapy cures need to be accessible in Africa

focus

knowledge

knowledge

explore